You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Docetaxel

Showing 1 - 25 of 3,166
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced NSCLC Trial (Trilaciclib+Envafolimab+Docetaxel, Envafolimab+Docetaxel, Docetaxel)

Not yet recruiting
  • Advanced Non-Small Cell Lung Cancer
  • (no location specified)
Jun 16, 2023

Prostate Cancer Trial in Chicago (Docetaxel, ADT, Abiraterone)

Not yet recruiting
  • Prostate Cancer
  • Docetaxel
  • +2 more
  • Chicago, Illinois
    Northwestern University
Sep 27, 2023

Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Tumors, Prostate Cancer Recurrent Trial (lorigerlimab,

Not yet recruiting
  • Androgen-Independent Prostatic Cancer
  • +8 more
  • lorigerlimab
  • +2 more
  • (no location specified)
May 4, 2023

Serplulimab,Gastric Cancer, Adjuvant Therapy Trial in Shanghai (Serplulimab, Docetaxel, S1)

Recruiting
  • Serplulimab,Gastric Cancer, Adjuvant Therapy
  • Shanghai, China
    Zhang Zizhen
Mar 3, 2023

NSCLC Trial (SGN-B6A, docetaxel)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • (no location specified)
Aug 21, 2023

Head Neck, Squamous Cell Carcinoma of Head and Neck Trial in Houston (Pembrolizumab, Magrolimab, cetuximab)

Not yet recruiting
  • Head Neck
  • Squamous Cell Carcinoma of Head and Neck
  • Houston, Texas
    M D Anderson Cancer Center
Sep 14, 2023

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Trial (PERT-IJS plus trastuzumab,

Not yet recruiting
  • HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
  • PERT-IJS plus trastuzumab, carboplatin and docetaxel
  • Perjeta plus trastuzumab, carboplatin and docetaxel
  • (no location specified)
Sep 21, 2023

Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer, Chemo Effect Trial in Nanjing (Docetaxel, Rezvilutamide)

Recruiting
  • Metastatic Prostate Cancer
  • +2 more
  • Nanjing, Jiangsu, China
    Urology dpt, First Affiliated Hospital of Nanjing Medical Univer
Aug 2, 2023

Metastatic Castration-resistant Prostate Cancer Trial (Darolutamide, Docetaxel or cabazitaxel)

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • (no location specified)
Feb 28, 2023

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Trial (Standard ADT (androgen deprivation therapy), Standard Darolutamide,

Not yet recruiting
  • Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
  • Standard ADT (androgen deprivation therapy)
  • +2 more
  • (no location specified)
Jan 6, 2023

Hormone Receptor Positive HER-2 Negative Breast Cancer Trial in Shanghai (Docetaxel, Carboplatin, Epirubicin)

Recruiting
  • Hormone Receptor Positive HER-2 Negative Breast Cancer
  • Docetaxel
  • +3 more
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Jun 12, 2023

NSCLC Stage IV, NSCLC Stage IIIB, NSCLC Stage IIIC Trial in China (Cadonilimab, Anlotinib, Docetaxel)

Recruiting
  • NSCLC Stage IV
  • +2 more
  • Hefei, Anhui, China
  • +4 more
Apr 15, 2023

Advanced or Metastatic Squamous NSCLC Trial in Sydney (HMBD-001, Docetaxel, Cetuximab)

Not yet recruiting
  • Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
  • Sydney, New South Wales, Australia
    GenesisCare North Shore
Jun 20, 2023

Non-small Cell Lung Adenocarcinoma, Squamous Cell Carcinoma of Lung Trial in Guangzhou (SI-B001, Docetaxel)

Not yet recruiting
  • Non-small Cell Lung Adenocarcinoma
  • Squamous Cell Carcinoma of Lung
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Jul 5, 2023

Prostate Cancer, Prostate Adenocarcinoma Trial in Charlotte (ADT+Docetaxel+Enzalutamide)

Active, not recruiting
  • Prostate Cancer
  • Prostate Adenocarcinoma
  • Charlotte, North Carolina
    Levine Cancer Institute
Jan 12, 2023

Prostate Cancer, Castrate Resistant Prostate Cancer Trial (Enzalutamide 40 MG, Docetaxel injection)

Not yet recruiting
  • Prostate Cancer
  • Castrate Resistant Prostate Cancer
  • Enzalutamide 40 MG
  • Docetaxel injection
  • (no location specified)
Jan 27, 2023

Locally Advanced Unresectable Esophageal Squamous Carcinoma Trial in Jinan, Tianjin (Docetaxel for Injection (Albumin-bound),

Not yet recruiting
  • Locally Advanced Unresectable Esophageal Squamous Carcinoma
  • Docetaxel for Injection (Albumin-bound)
  • +4 more
  • Jinan, Shandong, China
  • +1 more
Nov 16, 2023

Metastatic Prostatic Adenocarcinoma Trial in Charleston (Docetaxel, Degarelix)

Active, not recruiting
  • Metastatic Prostatic Adenocarcinoma
  • Charleston, South Carolina
    Medical University of South Carolina
Jan 30, 2023

NSCLC Trial in Beijing, Tianjin (TQB2450 injection, docetaxel injection matching , AL2846 capsules, TQB2450 matching , docetaxel

Recruiting
  • Non-small Cell Lung Cancer
  • TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules
  • TQB2450 matching placebo, docetaxel injection, AL2846 matching placebo
  • Beijing, Beijing, China
  • +2 more
Jun 19, 2023

NSCLC Trial in Guangzhou (Savolitinib, Docetaxel)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Department of Thoracic Surgery and Oncology, The First Affiliate
Mar 17, 2023

Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel Trial in Nanjing (Docetaxel injection, Triptorelin Pamoate for

Active, not recruiting
  • Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel
  • Docetaxel injection
  • +2 more
  • Nanjing, Jiangsu, China
    The Affiliated Nanjing Drum Tower Hospital of Nanjing University
Dec 24, 2022

HER2-positive Breast Cancer Trial in China (TQB2440 injection + Trastuzumab + Docetaxel, Perjeta + Trastuzumab + Docetaxel)

Active, not recruiting
  • HER2-positive Breast Cancer
  • TQB2440 injection + Trastuzumab + Docetaxel
  • Perjeta + Trastuzumab + Docetaxel
  • Chongqing, Chongqing, China
  • +5 more
Aug 3, 2023

Cohort Studies Trial in Jinan (apantamide+docetaxel+ADT, apantamide+ADT treatment)

Recruiting
  • Cohort Studies
  • Jinan, Shandong, China
    Qilu hospital
Feb 3, 2023

Locally Advanced or Metastatic NSCLC Trial (Utidelone Injection, Docetaxel Injection)

Not yet recruiting
  • Locally Advanced or Metastatic Non-Small Cell Lung Cancer
  • Utidelone Injection
  • Docetaxel Injection
  • (no location specified)
Dec 30, 2022

HER2-PositiveRecurrent or Metastatic Breast Cancer Trial (SHR-A1811 Injection, SHR-A1811 Injection ; Pertuzumab Injection,

Not yet recruiting
  • HER2-PositiveRecurrent or Metastatic Breast Cancer
  • SHR-A1811 Injection
  • +2 more
  • (no location specified)
Sep 21, 2023